In low-grade serous ovarian carcinoma the mitogen-activated protein kinase (MAPK) pathway is activated, a kinase cascade that mediates the transmission of growth signals into the nucleus, via mutations in KRAS and BRAF, the upstream regulators of the MAPK pathway. This evidence concerns the gene KRAS and ovarian serous carcinoma.